Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Clinical trial NCT05364073 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05364073
Sponsor: ArriVent BioPharma, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung Cancer Advanced Non-Small Cell Lung Cancer HER2 Exon 20 Mutations EGFR Exon 20 Mutations EGFR Uncommon Mutations, Including G719X and S768I

Start date: 2022-06-30
Primary completion: 2025-06-03
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.